To determine the criteria used in the current practice of neonatology for the initiation of home oxygen therapy in premature infants with bronchopulmonary dysplasia and to compare these criteria with the available literature regarding the use of home oxygen therapy.
INTRODUCTION
Considerable uncertainty exists regarding the specific criteria for the initiation of home oxygen therapy for infants with chronic lung disease. Despite over 20 years of experience with home oxygen therapy for infants with bronchopulmonary dysplasia (BPD), no consensus exists regarding specific indications for its use. 1, 2 In a previous study, we found large variations in criteria for the use of oxygen to treat premature infants at 36 weeks postmenstrual age (PMA). 3 In this current study, we wanted to determine if this same variability in practice extended into the use of home oxygen.
No randomized controlled trials have been performed to determine what pulse oximeter saturation (SpO 2 ) criteria should be used for the initiation and management of home oxygen therapy for BPD. In the absence of controlled studies regarding the effects of oxygen therapy to achieve a specific SpO 2 level in infants with BPD, recommendations can only be based on reference values from healthy infants and on observational studies regarding the pathophysiological effects of acute and chronic hypoxia.
In healthy term infants, the median baseline SpO 2 was found by Hunt et al. 4 to be 98%, with the 10th percentile being 95.2%. 4 Poets et al. 5 described similar levels of oxygen saturation (median SpO 2 of 99.5% with the fifth percentile being 95.7%) in healthy preterm infants at the time of hospital discharge (median gestational age 32.8±2.5 weeks). In a cohort of preterm infants (median gestational age 35 weeks) with no previous history of respiratory distress, Richard et al. 6 also found similar room air oxygen saturation levels with a mean SpO 2 of 99.4% and a fifth percentile of 99.5%. Ng et al. 7 demonstrated similar findings in a group of preterm infants (median gestational age 33 weeks, range 30 to 34 weeks) who had a mean SpO 2 of 97%. Both the Hunt and Ng studies used Ohmeda oximeters which yielded results 1.6% lower than the Nellcor oximeters used in the Richard and Poets studies. 8 Overall, the vast majority of healthy term and preterm infants at discharge have an oxygen saturation greater than 95% in room air with a median value of 99%.
Studies of infants with BPD have shown benefits from the use of oxygen at home. For example, home oxygen therapy has been shown to affect growth. In a retrospective study of infants with BPD, Groothuis and Rosenberg 9 found that home oxygen therapy targeted to maintain SpO 2 Z93% resulted in appropriate weight gain. However, when parents prematurely discontinued supplemental oxygen against medical advice, mean daily weight gain fell from 27.3 to 1.4 g/day. When home oxygen therapy was resumed, weight gain increased to18.3 g/day. Hudak et al. 10 also observed a similar effect on catch-up growth in 30 extremely lowbirth-weight infants with BPD (birth weight 783±24 g, gestational age 26±0.3 weeks). At hospital discharge, 77% of the infants were below the fifth percentile for weight. Home oxygen therapy was given to maintain SpO 2 Z95%. At the time of discontinuation of home oxygen therapy (median of 4.5 months), only 23% of the infants were still below the fifth percentile for weight. Moyer-Mileur et al. 11 prospectively evaluated 48 preterm infants with baseline SpO 2 levels of 88 to 91% versus Z92% at the time of discontinuation of home oxygen therapy. Infants in both groups showed a decrease in growth after oxygen was stopped. In the 88 to 91% group, weight gain decreased from 17.3 to 3.7 g/kg/day, whereas in the Z92% group weight gain decreased only slightly from 19.3 to 17.3 g/kg/day.
Supplemental oxygen therapy for infants with BPD has benefits beyond growth. The use of oxygen in infants with BPD to correct mild hypoxemia (SpO 2 89%) results in a 50% decrease in airway resistance, a significant increase in dynamic compliance and a decreased work of breathing. 12 Abman et al. 13 demonstrated a 50% decrease in pulmonary artery pressure when supplemental oxygen was used to increase SpO 2 from 82 to 93% in infants with severe BPD. The frequency of intermittent desaturation episodes (SpO 2 <80%) in infants with BPD was reduced from 5 to 0.2% by the use of oxygen targeted to maintain SpO 2 94 to 96%, compared to maintaining SpO 2 from 87 to 91%. 14 Furthermore, the incidence of sudden infant death syndrome in infants with BPD may be decreased by use of home oxygen therapy to keep SpO 2 Z93%.
15,16
A review on the use of supplemental oxygen by Poets 17 suggests that home oxygen therapy should be considered in infants whose room air SpO 2 is <93%, and that once started on home oxygen the SpO 2 should be maintained at Z95%. A second review by Kotecha and Allen 18 states that an SpO 2 <92% should be avoided, and a target range of at least 94 to 96% should be maintained. A third review by Abman 19 suggests maintaining the SpO 2 >92% in infants with BPD without pulmonary hypertension, and 94 to 96% in infants with BPD complicated by pulmonary hypertension. The American Academy of Pediatrics' Guidelines for Pediatric Home Health Care suggest use of oxygen in infants with BPD having baseline SpO 2 values <95% and targeting therapy to maintain SpO 2 95 to 98%. 20 The American Thoracic Society in a recent Statement on the Care of the Child with Chronic Lung Disease of Infancy and Childhood recommends that infants with BPD who are past the age of oxygen-induced retinopathy be provided with supplemental oxygen to achieve a saturation Z95%. 21 As a whole, the above reviews would suggest a threshold SpO 2 of <92 to <95% for the initiation of home oxygen therapy in infants with BPD, with a target saturation of at least Z94%. Whether any of the above practices or another standard is employed among neonatologists is unknown. Thus, our objective was to determine the current practice among neonatologists regarding the use of supplemental oxygen at home and compare these criteria with the available literature regarding home oxygen use in infants with BPD.
METHODS
We surveyed participants at the December 2000 meeting of the Vermont Oxford Network (VON) regarding their criteria for the use of home oxygen therapy for treatment of infants with BPD. BPD was defined as oxygen dependence at 36 weeks PMA. 22 We chose to survey the VON because of the wide geographic (48 states and 20 countries) and clinical range (private practice to university) of its members. Although permission for distribution of the survey was obtained from the VON, it was not involved in the design or content of the survey. The survey included the following questions:
(1) What baseline SpO 2 on room air would you consider low enough to warrant home supplemental oxygen therapy? Possible answers: <84, <86, <88, <90, <92, <94, <96 and <98%. 
RESULTS
Home Oxygen Therapy Surveys were completed and returned by 181 of the 297 participants (61%) attending the December 2000 meeting of the Vermont Oxford Network. The VON did not allow identification of center affiliation and thus some responses may have come from the same center leading to the possibility that less than 181 centers were represented. We found a wide range in the threshold SpO 2 for the administration of home oxygen, from <84 to <96%, with 64% of respondents not initiating home oxygen until the SpO 2 was below 90% (Figure 1 ). If Poets' 17 recommended threshold of 93% is used as a reference, then up to 88% of all respondents would not initiate home oxygen therapy (Figure 1 ). An oxygen saturation level of <90% was most often chosen as the threshold at which home oxygen was initiated, however, this same target was chosen by only 43% of the respondents.
Once on home oxygen therapy, the goal SpO 2 also varied widely, ranging from a target SpO 2 of >84 to >98%, with only 27% of respondents targeting an SpO 2 of >94% (Figure 2) . Again, there was therapeutic inconsistency among the respondents with only 34% using the same target saturation of >90%.
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There were reasons other than abnormal SpO 2 values in room air given for the use of supplemental oxygen at home. The use of home oxygen therapy was considered by 51% of the respondents for the treatment of an infant with a ''normal SpO 2 '' on room air who had tachypnea, tachycardia, and/or poor growth. Out of the remaining 49% of the respondents who would not consider oxygen for these indications; 12% advocated red blood cell transfusion as a preferred therapy, 6% listed corticosteroids, and 8% would pursue an ''additional evaluation''.
DISCUSSION
Recently, a survey of departments of pediatrics in Germany of criteria for the use of home oxygen therapy in infants found that the SpO 2 thresholds for oxygen varied widely (80 to 94%) with 93% of respondents using SpO 2 thresholds lower than Poets' recommendation (<93% saturation to initiate or continue supplemental oxygen in premature infants with BPD). The targeted SpO 2 goal once on oxygen therapy was also found to vary widely from 86 to 100% saturation, with 68% using a target SpO 2 that was again less than Poets' 1 recommendation of Z95%. A separate study in the United Kingdom and Ireland also addressed criteria for the discontinuation of home oxygen therapy in infants with BPD. Consistent with the study from Germany, they found a wide range of SpO 2 thresholds (85 to 98%) with 46% again using a threshold less than Poets' recommendation. 2 It is clear that this practice pattern is not unique to a specific country and may actually be representative of a global inconsistency in the use of home oxygen therapy.
We found, in agreement with the above studies, that the majority of Vermont Oxford Network neonatologists surveyed also used SpO 2 criteria well below the recommendations of Poets, Kotecha, Abman and the American Academy of Pediatrics. [17] [18] [19] Despite observational data spanning nearly 20 years, nearly 90% of respondents used SpO 2 thresholds for the initiation and maintenance of home oxygen therapy below the levels recommended by the medical literature. The reasons for the discrepancy between the SpO 2 thresholds currently supported by the literature and thresholds commonly used in clinical practice for home oxygen therapy are unclear.
Our survey did not explore the rationale for the reluctance to use home oxygen therapy for infants with BPD. Factors possibly affecting the decision to continue or initiate home oxygen therapy could include cost, parental stress or anxiety and oxygen toxicity. Concerns over home oxygen therapy increasing the overall costs of medical care have not been substantiated. In fact, home oxygen therapy has been shown to decrease health-care costs. Thilo et al. 23 calculated an average estimated savings of $33,370 for each infant discharged on home oxygen therapy. McAleese et al. 24 found a similar savings of $41,725 per infant, although the cost savings were primarily for third-party payors and hospitals with an increase in out-of-pocket costs to the patients.
Physicians may be reluctant to prescribe home oxygen therapy because it may increase parental stress. It is true that parental stress, anxiety and inconvenience are increased transiently with home oxygen therapy, but overall this form of outpatient therapy is well accepted by parents and is in fact preferred to ongoing hospitalization. [23] [24] [25] [26] [27] Physician concern over oxygen toxicity may be another reason limiting the use of home oxygen. The acceptance of lower SpO 2 values rather than starting home oxygen therapy could possibly be related to the use of SpO 2 levels <94% early in a premature infant's course to minimize both the risk of retinopathy of prematurity (ROP) and pulmonary oxygen toxicity from exposure to high levels of oxygen.
An observational study by Tin et al. 28 has shown that by maintaining oxygen saturations 70 to 90% versus 88 to 98%, the incidence of ROP and BPD was reduced and growth was less 
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Home Oxygen and Bronchopulmonary Dysplasia impaired. This practice was primarily used in the first 2 months of life and is not relevant for home oxygen therapy. In fact, liberal oxygen supplementation was employed by Tin et al, 28 in infants with BPD who were older than 8 weeks with mature retinal vasculature. The above concern over SpO 2 levels >94% increasing the risk for ROP is not supported at the older PMA at which an infant would be considered for discharge on home oxygen. In fact, the STOP-ROP study, with a mean PMA at entry of 35 weeks, demonstrated no worsening to a slight decrease in progression from prethreshold to threshold ROP when SpO 2 was kept >94% (96 to 99% versus 89 to 94%). However, pulmonary oxygen toxicity was slightly increased in the high-saturation group, possibly reflecting elevated inspired oxygen concentrations for a subset of these patients, as the mean fractional inspired oxygen concentration in this group was relatively high at 0.46±0.20 after randomization. 29 Thus, the potential for exposure to toxic concentrations of oxygen could be minimized during home oxygen therapy by limiting nasal cannula flow rates. 30 The recently completed BOOST trial studied infants requiring oxygen at 32 weeks PMA with the SpO 2 targeted to either 91 to 94% or 95 to 98%. No beneficial differences were seen between groups at 1 year of age from targeting a higher saturation level. 31 However, this population is not comparable to patients discharged on home oxygen since the BOOST trial reflects a much younger hospitalized group of patients at 32 weeks PMA versus the much older, at least 36 weeks PMA, patient with BPD. Furthermore, the BOOST trial did not include a group in which SpO 2 levels of 90% or less were tolerated. A saturation level at which the majority (64%) of the neonatologists in our survey (Figure 1) would not implement home oxygen therapy.
Our study has several limitations. Responses were self-reported perceptions subject to recall bias and selective participation. There were no standardized conditions required for the state of the infant at the time at which the SpO 2 was measured. The survey was completed by only 61% of the targeted VON audience, views of the nonresponders may potentially have influenced the results and there may have been multiple responders from the same institution.
We found a wide variation in the oxygen saturation levels used for the implementation of home oxygen therapy for infants with BPD. The majority of neonatologists surveyed used SpO 2 levels not well supported by the available literature. Furthermore, even when employed, home oxygen therapy is not optimized. We speculate that a significant underutilization of home oxygen therapy exists for infants with BPD. The decision to use supplemental home oxygen therapy to keep saturations Z94 versus Z90% remains controversial. Clear guidelines in this area would require large, randomized clinical trials to examine the impact of these different saturation levels on long-term outcomes. In lieu of such trials, one should consider the potential benefits versus risks of utilizing home oxygen for infants with BPD whose room air saturations are <94%.
